Potential IL2 Substitute Shrinks Solid Tumors

Abstract

Abstract Nemvaleukin alfa, an engineered cytokine that may induce the tumor-fighting benefits of IL2 without the side effects, has demonstrated effectiveness against solid tumors. As a monotherapy, the drug produced overall response rates of 13% in patients with advanced melanoma and 18.2% in advanced renal cell carcinoma. When combined with pembrolizumab, the drug produced responses in 16.1% of patients with various solid tumor types.